AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10362413
Drug: 546C88 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 546C88 at 5 mg/kg/hr
Trial: 10362413
Drug: 546C88 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 546C88 at 10 mg/kg/hr
Trial: 10362413
Drug: 546C88 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 546C88 at 20 mg/kg/hr
Trial: 8750372
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg alone
Trial: 8750372
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg with losartan 50 mg
Trial: 2053226
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of norfenefrine
Trial: 6365516
Drug: Milk-based formula
RxNorm normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based formula supplement providing 800 kcal and 40 g protein daily
Trial: 6365516
Drug: Milk-based formula
RxNorm normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based formula supplement
Trial: 30711327
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with lavender essence
Trial: 27767433
Drug: Acupuncture (n=15);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (n=15); treatment for 30 days, once weekly for 5 sessions.
Trial: 27767433
Drug: Carprofen (4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (4.4 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Trial: 27767433
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose capsules, 1 mg/kg, PO, q 24 h; n=16); treatment for 30 days.
Trial: 24072404
Drug: Implant removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant removal patients (N=38)
Trial: 20930165
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (multicomponent treatment including aspirin)
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 2 cm and infused semen volume of 0.3 ml
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 1 cm and infused semen volume of 0.5 ml
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 1 cm and infused semen volume of 0.3 ml
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 2 cm and infused semen volume of 0.5 ml
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 3 cm and infused semen volume of 0.5 ml
Trial: 14689885
Drug: Catheter depth
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter depth of 3 cm and infused semen volume of 0.3 ml
Trial: 10494584
Drug: Intravenous nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nicotine (0, 3.5, 7, 14, and 28 micrograms/kg)
Trial: 1816570
Drug: Triazolam (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125, 0.25 and 0.5 mg/70 kg of body weight)
Trial: 6752963
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diazepam suppositories
Trial: 22704391
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL saline solution im)
Trial: 17379432
Drug: Cevimeline 30
RxNorm normalized name: Cevimeline 30mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline 30 mg three times daily (with possible escalation to 45 mg)
Trial: 17379432
Drug: Cevimeline 30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline 30-45 mg three times daily
Trial: 25992746
Drug: Fixed course
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed course of antibiotics for 4±1 calendar days
Trial: 25992746
Drug: Antibiotics until
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics until 2 days after resolution of fever, leukocytosis, and ileus, maximum of 10 days
Trial: 19696287
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material of 300 mg I/mL (Protocol A)
Trial: 19696287
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material of 370 mg I/mL (Protocol B)
Trial: 19696287
Drug: Contrast material
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast material of 370 mg I/mL plus saline flush (Protocol C)
Trial: 16809571
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin (ALB) infusion, doses ranging from 0.34 to 2.05 g/kg, administered over 2 hours within 16 hours of stroke onset
Trial: 16809571
Drug: Standard-of-care intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care intravenous tissue plasminogen activator (tPA)
Trial: 12777860
Drug: Anti-CD25 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD25 monoclonal antibody (daclizumab)
Trial: 1540491
Drug: (+)-R-nitrendipine 20
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-R-nitrendipine 20 mg
Trial: 1540491
Drug: (-)-S-nitrendipine 20
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-S-nitrendipine 20 mg
Trial: 1540491
Drug: R,S-nitrendipine (pseudoracemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R,S-nitrendipine (pseudoracemic mixture of 10 mg (+)-R and 10 mg (-)-S)
Trial: 31982540
Drug: Regular paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular paracetamol
Trial: 31982540
Drug: Paracetamol as-needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol as-needed
Trial: 26543177
Drug: v‐gel supraglottic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: v‐gel supraglottic airway device (SGAD)
Trial: 19147639
Drug: Topical chloramphenicol
RxNorm normalized name: chloramphenicol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical chloramphenicol (n=488)
Trial: 19147639
Drug: Paraffin ointment
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin ointment (n=484; placebo)
Trial: 16785075
Drug: Citracal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citracal tablet providing 315 mg of elemental calcium
Trial: 16785075
Drug: OsCal tablet
RxNorm normalized name: OsCal 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OsCal tablet providing 500 mg of elemental calcium
Trial: 16785075
Drug: People's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: People's Choice tablet providing 600 mg of elemental calcium
Trial: 16785075
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablet
Trial: 11034038
Drug: Oral phytonadione
RxNorm normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phytonadione 2.5 mg
Trial: 9063425
Drug: Antihistamine-decongestant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-decongestant combination (ADC) - brompheniramine maleate-phenylpropanolamine hydrochloride
Trial: 9063425
Drug: Antihistamine-decongestant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-decongestant combination (ADC)
Trial: 7981078
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (Peptichemio, vincristine, and prednisone)
Trial: 7981078
Drug: MPH-P and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH-P and combination chemotherapy
Trial: 4527847
Drug: CAPA (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPA (cyclophosphamide, cytosine arabinoside, prednisolone, and L asparaginase)
Trial: 26135582
Drug: Pharmacist in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist in a community pharmacy with predefined training in performing medication reviews
Trial: 18192779
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy in primary HIV infection
Trial: 18192779
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy of a limited duration
Trial: 12911201
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 microg x kg(‐1)) and propofol (1.8 mg x kg(‐1))
Trial: 12911201
Drug: N2O/sevoflurane (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2O/sevoflurane (4% sevoflurane in N2O at 41 x min(‐1) and oxygen at 21 min(‐1)) and propofol (1.8 mg x kg(‐1))
Trial: 9315416
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection of local anesthetics (n = 31), paracervical block involving four injections approximately 3 cm deep
Trial: 9315416
Drug: Regular injection
RxNorm normalized name: diluent,insulin lispro,regular INJECTION VIAL (ML)
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular injection of local anesthetics (n = 35), paracervical block involving four injections approximately 1.5 cm deep
Trial: 9315416
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection of local anesthetics (n = 31)
Trial: 9315416
Drug: Regular injection
RxNorm normalized name: diluent,insulin lispro,regular INJECTION VIAL (ML)
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular injection of local anesthetics (n = 35)
Trial: 8436146
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg t.i.d. as additive treatment to morphine
Trial: 3014855
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (500 mg elemental calcium)
Trial: 3014855
Drug: Hydroxyapatite (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite (500 mg elemental calcium)
Trial: 27574730
Drug: Conditioning procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning procedure on pain tolerance with belief in analgesic treatment (Experiment 1)
Trial: 23039403
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once a day
Trial: 22726241
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) 0.4, 0.6 and/or 0.8 U/kg once daily for two 6-day periods
Trial: 8941691
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg daily, starting from the 3rd postoperative day (14 patients)
Trial: 3533127
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg biphasic release formulation twice daily)
Trial: 27513404
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac sodium 75 mg
Trial: 27513404
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac sodium 100 mg
Trial: 24864182
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 g/1.73 m2 per day for 3 days)
Trial: 16316558
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/d for 6 months
Trial: 16316558
Drug: Ticlopidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 500 mg/d for 1 month
Trial: 12854625
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler with spacer
Trial: 10584041
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (5 g/MJ, 19% of total energy)
Trial: 10584041
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (5 g/MJ, 19% of total energy)
Trial: 10584041
Drug: Rapeseed oil
RxNorm normalized name: Rapeseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed oil (5 g/MJ, 19% of total energy)
Trial: 8651516
Drug: Manual disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual disinfection procedures using five disinfectants (two 2% alkaline glutaraldehyde preparations, 3.2% alkaline glutaraldehyde, 75 ppm iodophor, and 0.5% glutaraldehyde-0.03% phenolic)
Trial: 2009789
Drug: Aerosolized BN52021
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized BN52021 (PAF antagonist)
Trial: 7010650
Drug: 4% HSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% HSA in Ringer's lactate solution (RL) resuscitation
Trial: 7010650
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution (RL) resuscitation
Trial: 27914846
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone acetonide injection
Trial: 27914846
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone acetonide injection
Trial: 24092240
Drug: Western music
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western music therapy
Trial: 19756348
Drug: PTH(1-84) 100
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH(1-84) 100 mcg
Trial: 19756348
Drug: PTH(1-34) 20
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH(1-34) 20 mcg
Trial: 15118187
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (40 g protein/d)
Trial: 15118187
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (40 g protein/d)
Trial: 9498442
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated chikungunya virus (CHIKV) vaccine
Trial: 9498442
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VEEV vaccine
Trial: 7919944
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg to 50 mg)
Trial: 2838231
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 X 1 mg/day for 1 week)
Trial: 25376930
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch monotherapy
Trial: 25376930
Drug: Memantine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine plus rivastigmine transdermal patch therapy
Trial: 25376930
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch or memantine add‐on therapy
Trial: 21414183
Drug: Myoinositol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoinositol supplementation (4 g daily) plus folic acid (400 μg daily)
Trial: 21414183
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid only (400 μg daily)
Trial: 17046467
Drug: No antimalarial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimalarial drugs
Trial: 12670066
Drug: Hybrid composite
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid composite (Tetric) plus adhesive bonding agent (Syntac Classic)
Trial: 12670066
Drug: Compomer (Dyract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer (Dyract AP) plus adhesive bonding agent (Prime & Bond NT)
Trial: 11074747
Drug: Once-daily enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily enoxaparin
Trial: 8753708
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cephapirin sodium and gentamicin for three days
Trial: 8753708
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ciprofloxacin for three days
Trial: 3574639
Drug: Flupentixol 2
RxNorm normalized name: flupenthixol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 2 mg/day
Trial: 3574639
Drug: Flupentixol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 1 mg/day
Trial: 3574639
Drug: Flupentixol 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 0 mg/day (control)
Trial: 3574639
Drug: Flupentixol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol (0, 1, and 2 mg)
Trial: 29943163
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg for 8 weeks
Trial: 29799875
Drug: Tenofovir-containing vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir-containing vaginal gel or insert
Trial: 29799875
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo products (vaginal gel or insert)
Trial: 22745573
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine iv bolus
Trial: 22745573
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg iv paracetamol infusion
Trial: 17126520
Drug: Percutaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous treatment with expanded polytetrafluoroethylene (ePTFE)/nitinol self‐expanding stent grafts
Trial: 10320254
Drug: Venoarterial pedicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venoarterial pedicle preparation (group B)
Trial: 25159623
Drug: Fast atazanavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast atazanavir clearance (≥9 L/h) in females
Trial: 25159623
Drug: Slow atazanavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow atazanavir clearance (<7 L/h) in males
Trial: 25159623
Drug: Middle atazanavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle atazanavir clearance (7 to <9 L/h)
Trial: 9717867
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy for weeks 1 to 16
Trial: 9717867
Drug: Fluvoxamine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine for weeks 1 to 16 plus cognitive therapy in weeks 9 to 16
Trial: 7656956
Drug: Ambulatory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory oxygen at 2 L.min‐1
Trial: 2663737
Drug: Cephradine 2
RxNorm normalized name: cephradine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine 2 g intravenously
Trial: 2663737
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g intravenously
Trial: 205226
Drug: digoxin/silica matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin/silica matrix tablets (Digacin)
Trial: 205226
Drug: digoxin/silica matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin/silica matrix in capsule form
Trial: 205226
Drug: digoxin/silica matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin/silica matrix formulations (in vitro)
Trial: 205226
Drug: conventional tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional tablets from digoxin-lactose trituration (in vitro)
Trial: 28654304
Drug: Active continuous
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active continuous diffusion of oxygen (CDO) therapy
Trial: 28654304
Drug: Sham device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham device providing moist wound therapy (MWT)
Trial: 25453567
Drug: Chlorhexidine (CHX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX), 2% CHX gel
Trial: 25453567
Drug: Ca(OH)2/CHX, Ca(OH)2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2/CHX, Ca(OH)2 + 2% CHX gel